Darzalex Faspro (daratumumab + hyaluronidase-fihj) — HCPCS J9144
CareCost Estimate · Billing Cheat Sheet
Janssen Biotech (J&J)
1,800 mg / 30,000 U / 15 mL single-dose vial
SC injection over 3–5 minutes (FIXED dose)
Reviewed: May 2, 2026
ASP: Q2 2026
Dose
180 units
1,800 mg SC FIXED · 1 vial
Modifier
JZ
Required · NEVER JW
Admin CPT
96401
Chemo SC, non-hormonal
Medicare ASP+6%
$55.032
/unit · $9,905.76/dose
SC ≠ IV. J9144 (Faspro, SC) = fixed 1,800 mg = 180 units, always. J9145 (Darzalex, IV) = weight-based 16 mg/kg, ~120–160 units, varies. Wrong code = denial or major billing error. Verify formulation in encounter notes BEFORE billing.
Codes & NDC
| HCPCS | J9144 — "Daratumumab, hyaluronidase-fihj, 10 mg" (permanent J-code) |
|---|
| NDC | 57894-502-01 (10) / 57894-0502-01 (11) — N4 qualifier |
|---|
| Vial | 1,800 mg + 30,000 U / 15 mL (120 mg/mL + 2,000 U/mL) single-dose |
|---|
| IV cousin | Darzalex IV (daratumumab, J9145) — Janssen, weight-based 16 mg/kg |
|---|
| Benefit | Medical (provider buy-and-bill); not specialty pharmacy |
|---|
Dosing — FIXED 1,800 mg
- 1,800 mg SC over 3–5 min in abdomen (~3 in. R or L of navel) — not weight-based
- Same dose for 50 kg or 120 kg patient
- Schedule (mirrors IV daratumumab):
- Weekly, weeks 1–8
- Every 2 weeks, weeks 9–24
- Every 4 weeks, week 25 onward
- 1 vial per dose · always 180 units billed
- Year-1 typical: ~23 doses = ~4,140 units
SC vs IV — every axis differs
| Axis | J9144 (SC) | J9145 (IV) |
|---|
| Dose model | Fixed 1,800 mg | 16 mg/kg (weight) |
| Units | 180 (always) | ~120–160 (varies) |
| Admin CPT | 96401 | 96413 + 96415 |
| Time | 3–5 min injection | 3–7 hr first dose |
| Wastage | JZ (full vial) | JZ + JW (partial) |
| AL amyloidosis | YES | NO |
Administration & modifiers
| Code | When |
|---|
96401 | Chemo SC, non-hormonal — primary (oncology biologic) |
96372 | Therapeutic SC — fallback if 96401 denied |
96413/96415 | NEVER — IV codes for J9145 only |
JZ required, JW does NOT apply. Full 1,800 mg vial used for fixed dose = no waste. Carrying JW habit from J9145 = denial trigger.
340B: JG (standard) or TB (informational alt) per MAC. Verify current policy.
ICD-10 — Multiple Myeloma (primary)
| Code | For |
|---|
C90.00 | MM not in remission (newly dx / active) |
C90.01 | MM in remission (maintenance) |
C90.02 | MM in relapse (R/R) |
C90 | AVOID — parent code, payers reject |
ICD-10 — AL Amyloidosis (J9144 ONLY)
| Code | For |
|---|
E85.81 | Light chain (AL) amyloidosis — newly dx, with D-VCd |
E85.82 | Wild-type ATTR — NOT covered by J9144 |
E85.89 | Other amyloidosis — caution; payers down-code |
AL is J9144-only. The IV form J9145 has NO AL amyloidosis indication. Newly dx AL = Faspro required (only FDA-approved tx for newly dx AL).
Payer requirements (May 2026)
| Payer | PA | Prefers SC? |
|---|
| UnitedHealthcare | Yes | Yes · steers to office |
| Aetna | Yes | Yes · some plans step IV→SC after C1 |
| Cigna | Yes | Yes |
| Anthem / Carelon | Yes | Often (regional) |
| BCBS (regional) | Yes | Yes (most regions) |
Site-of-care steering is real. Faspro preferred at most national payers — drives SC over IV. Verify before initiating IV.
Medicare reimbursement (Q2 2026)
| Field | Value |
|---|
| ASP + 6% | $55.032 / 10 mg unit (eff. 4/1 – 6/30/2026) |
| 1,800 mg dose | $9,905.76 (180 × $55.032) |
| After sequestration (~2%) | ~$9,708 (actual paid) |
| Year-1 (~23 doses) | ~$227,832 |
Site of care
| Setting | POS | Notes |
|---|
| Oncology office | 11 | Preferred · 30-min visit |
| Ambulatory infusion | 49 | Common · short slot OK |
| Hospital outpatient | 19/22 | Payers steer away |
| Patient home | 12 | Limited oncology vendors |
Patient assistance — Janssen CarePath
- Phone: 1-877-CarePath (1-877-227-3728) M–F 8a–8p ET
- Commercial copay: $0 first dose, then up to ~$20,000/year
- J&J Patient Assistance Foundation: free drug for uninsured/Medicare hardship
- Independent foundations (Medicare): LLS Co-Pay, HealthWell (MM fund), PAN, PAF Co-Pay Relief
- Web: janssencarepath.com · darzalex.com
TYPE & SCREEN BEFORE FIRST DOSE. Daratumumab binds CD38 on RBCs — interferes with indirect Coombs, masks minor antibodies (pan-reactive). Document baseline ABO/Rh + antibody panel BEFORE first dose. Notify blood bank for transfusions up to 6 mo post-last-dose. Injection-site rxns 7–12% (vs IV infusion rxns).